1. ANNIVERSARY REVIEW: Octreotide, 40 years later
Steven W J Lamberts, Leo J Hofland Eur J Endocrinol. 2019 Nov;181(5):R173-R183. doi: 10.1530/EJE-19-0074.
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide.
2. Octreotide
Gregory V Stajich, Laurel Ashworth Neonatal Netw. 2006 Sep-Oct;25(5):365-9. doi: 10.1891/0730-0832.25.5.365.
The use of SC or IV octreotide, a long-acting synthetic analog of somatostatin, provides a promising pharmacologic approach to reducing drainage in selected patients with a congenital or postoperative chylothorax, who do not respond to conservative treatment strategies. Prompt institution of octreotide therapy after surgery in patients with significant drainage or the formation of chyle may reduce the expense and morbidity associated with a prolonged hospital stay. Given the individual variability in patient response to octreotide and the limited clinical data regarding its use in the pediatric population, octreotide therapy must be individualized with careful consideration being given to possible benefits versus inherent risks.
3. Evolution of Neuroendocrine Tumor Therapy
Thomas M O'Dorisio, Alan G Harris, M Sue O'Dorisio Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002.
To better understand developments in treatment of neuroendocrine tumors of the gastroenteropancreatic system, and the pivotal roles of native somatostatin and its long-acting analogues play in normal peptide regulation and neuropeptide excess associated with neuroendocrine tumors (NETs), this article delineates and defines distinct eras in the history and discovery of gastrointestinal endocrinology. We highlight the collaboration between academia and industry in basic science and the clinical research that advanced Lu-177-DOTATATE to approval as standard of care therapy for low-grade NETs. Examples of new radioisotopes and therapy compounds currently in development for diagnosis and therapy for high-grade NETs are also discussed.
